mGluR4 positive allosteric modulators with potential for the treatment of Parkinson's disease: WO09010455.
Stimulation of the metabotropic glutamate receptor 4 (mGluR4) represents a promising new approach to the symptomatic treatment of the neurodegenerative disorder Parkinson's disease (PD). Preclinical models using both agonists and positive allosteric modulators of mGluR4 have demonstrated the potential for this receptor for the treatment of PD. The present article evaluates a recent patent filed by Addex Pharma S.A. claiming a novel series of mGluR4 positive allosteric modulators. Many of the examples disclosed are active at EC(50)'s < 500 nM.
East
Stephen P
SP
Evotec (UK) Ltd, 114 Milton Park, Abingdon, OX14 4SA, UK. stephen.east@evotec.com
Gerlach
Kai
K
D000494:Allosteric Regulation; D000818:Animals; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010330:Patents as Topic; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects* / Q000378:metabolism
D000978:Antiparkinson Agents; D018094:Receptors, Metabotropic Glutamate; C108823:metabotropic glutamate receptor 4